



European ME Alliance, Sønder Alle 5, st 3, 9500 Hobro, Denmark

Email: [info@euro-me.org](mailto:info@euro-me.org)

web: [www.euro-me.org](http://www.euro-me.org)

**LA SITUATION JURIDIQUE ET MÉDICALE DES PATIENTS DE L'E.M. (ENCEPHALOMYÉLITE MYALGIQUE) ET LA SFC (SYNDROME DE FATIGUE CHRONIQUE)**

L' Encephalomyélite Myalgique (EM) a été accepté déjà en 1969 par l' **OMS** comme une maladie neurologique.

Dans certains pays l' EM est appelé Syndrome de Fatigue Chronique (SFC). En 1993 l' SFC a été ajouté comme un additif de l' ICD-10. Le mot "fatigue" -selon la définition de l' SFC - reste toujours source de confusion et cause de nombreux problèmes pour les patients, comme a déclaré Mme Androulla Vassiliou, ancien Commissaire Européen chargé de la Santé.

L' EM peut se manifester en épidémies: une a été décrite pour la première fois en 1934.

Des experts de l' EM l'ont placé dans la même catégorie que le cancer et le dernier stade du SIDA concernant la qualité de la vie et de la souffrance.

**C'est la raison pour laquelle nous demandons ce qui suit :**

- à respecter le Code de l'OMS G93.3 pour l' EM comme une maladie neurologique et veiller à ce que les États membres mettent ceci en œuvre dans leur système de soins de santé;

-de respecter les droits du patient - y compris des enfants - dans tous les États membres;

- d'approuver en tant que critères de diagnostic pour l'E.M. les Canadian Consensus Criteria et le développement des Consensus de Critères Internationaux;

- à encourager le développement de la recherche biomédical.

**Environ 1.200.000 de très malades patients atteints par l'E.M. en Europe sont en attente pour que le parlement reconnaisse le Code de l'OMS G93.3.**



European ME Alliance, Sønder Alle 5, st 3, 9500 Hobro, Denmark

Email: [info@euro-me.org](mailto:info@euro-me.org)

web: [www.euro-me.org](http://www.euro-me.org)

## References

1. [www.who.int/classifications/icf](http://www.who.int/classifications/icf)  
  
G93.3 Postviral fatigue syndrome  
Benign myalgic encephalomyelitis (ME)
2. Carruthers B, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Basted AC, Flor-Henry P, Joshi P, Powles AP, *et al.*: Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *Journal of chronic fatigue syndrome* 2003, 11(1):7-115.
3. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T *et al.* Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med* 2011;270:327-38.
4. Nacul LC, Lacerda EM, Champion P, Pheby D, Drachler MD, Leite JC, Poland F, Howe A, Fayyaz S, Molokhia M: The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health* 2011, 11(1):402.
5. J. Mark Van Ness, Staci R. Stevens, Kylie T. Kumasaka, Harnoor Singh, Betsy Keller, Daniel L. Peterson, Jose Montoya and Christopher R. Snell: A diagnostic test for the identification of metabolic dysfunction. *Conference abstract 9th IACFS/ME clinical and research conference, Reno, March 7, 2009.*
6. Brown, M. M., Bell, D. S., Jason, L. A., Christos, C. and Bell, D. E. (2012), Understanding Long-Term Outcomes of Chronic Fatigue Syndrome. *J. Clin. Psychol.*, 68: 1028-1035. doi: 10.1002/jclp.21880
7. Twisk, F.N., Maes, M., 2009. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/ chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. *Neuro Endocrinology Letters* 30 (3), 284-299.
8. KCE report: Evaluation of CBT/GET therapy.  
<https://kce.fgov.be/nl?SGREF=5268&CREF=11648>
9. Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, *et al.* (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. *PLoS ONE* 6(10): e26358. doi:10.1371/journal.pone.0026358
10. Maes M, Twisk FN: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. *BMC Med* 8:35.
11. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. *Brain Behav Immun.* 2010 Oct;24(7):1209-17.
12. Komaroff AL, Cho TA: Role of infection and neurologic dysfunction in chronic fatigue syndrome. *Seminars in Neurology* 2011, in press.



European ME Alliance, Sønder Alle 5, st 3, 9500 Hobro, Denmark

Email: [info@euro-me.org](mailto:info@euro-me.org)

web: [www.euro-me.org](http://www.euro-me.org)

### For further information

1. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. *J Clin Microbiol* 1990; 28: 1403-10. [PMID: 2166084]
2. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. *Int J Clin Exp Med* 2009; 2: 1-16. [PMID: 19436827]
3. Peckerman, A., LaManca, J.J., Dahl, K.A., Chemitiganti, R., Qureishi, B., Nattelsson, B.H., 2003. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. *American Journal of Medical Sciences* 326 (2), 55-60.
4. Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. *Am J Med* 2000; 320: 1-8. [PMID: 10910366]
5. Kerr JR, Burke B, Petty R, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis; a detailed analysis of gene network and clinical phenotypes. *J Clin Pathol* 2008; 61: 730-739. [PMID: 18057078]
6. Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlin G. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. *Amer J Med* 1998; 105: 54S-8S. [PMID: 9790483]
7. Goldstein JA. *Chronic Fatigue Syndrome: The Limbic Hypothesis*. Binghampton, New York: Haworth Medical Press; 1993:19, 116.
8. Chia J, Chia A, Voeller M, Lee T, Chang R. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome and viral persistence. *J Clin Pathol* 2010; 63: 163-8. [PMID: 19828908]
9. Pall ML. *Explaining "Unexplained Illnesses": Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others*. Binghamton, NY: Harrington Park (Haworth) Press, 2007.
10. Meeus M, Nijs J, McGregor N, Meeusen R, De Schutter G, Truijzen S, Frémont M, Van Hoof E, De Meirleir K.: Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. *In Vivo*. 2008 Jan-Feb;22(1):115-21. PMID:18396793 [PubMed - indexed for MEDLINE] Free Article

For an objective view of the establishment intrigue surrounding ME we recommend:

**Magical Medicine: How to Make a Disease Disappear** by Professor Malcolm Hooper [ [www.investinme.org/Article400%20Magical%20Medicine.htm](http://www.investinme.org/Article400%20Magical%20Medicine.htm) ]

Professor Hooper has made a formal complaint to the Minister of State responsible for the Medical Research Council.